Browse by author
Lookup NU author(s): Professor Chris Day
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Alcoholic liver disease (ALD) and its complications is still one of the most frequent causes of death in the Western world. Treatment modalities for both alcoholic steatohepatitis (ASH; the major inflammatory complication of ALD) and alcoholic liver cirrhosis are insufficient. Severe ASH is associated with a high mortality; although glucocorticoid treatment has been reported to improve survival, meta-analyses of clinical trials performed to date have failed to show a convincing benefit of such an approach. Most of the progress in understanding these diseases, especially ASH, has come from studies of cytokines. Various proinflammatory cytokines, such as tumor necrosis factor (TNF), have been proposed to have an important role in the pathophysiology of ALD and its complications. Pilot studies on the use of anti-TNF drugs, such as pentoxifylline or infliximab, in the treatment of ASH have now been performed with various levels of success. The treatment of patients with alcohol-related cirrhosis is mainly symptomatic and no therapies are currently available except orthotopic liver transplantation for end-stage liver disease. Independent of the stage of disease, abstinence from alcohol is the cornerstone of management. New treatment modalities for these diseases are eagerly awaited.
Author(s): Tilg H, Day CP
Publication type: Review
Publication status: Published
Journal: Nature Clinical Practice Gastroenterology and Hepatology
Year: 2007
Volume: 4
Issue: 1
Pages: 24-34
Print publication date: 01/01/2007
ISSN (print): 1759-5045
ISSN (electronic): 1759-5053
URL: http://dx.doi.org/10.1038/ncpgasthep0683
DOI: 10.1038/ncpgasthep0683
PubMed id: 17203086
